least this version of it. and it will be interesting to see if the language changes around when they will raise rates. >> and if the fed is boring, on friday we'll get the employment cost, the most comprehensive measure of age growth. >> we have to leave it right there. you'll have to save it for afterwards or something. everybody, thank you so much for being here. and "fast money" begins right now. live from the nasdaq market site in new york city's times square, this is "fast money." i'm melissa lee. traders are sim seymour, karen finerman. twitter selling off shares after the company's number of monthly active users came in below expectations. is this a buying opportunity? twitter's conference call starting right now. suntrust monitoring that call for us. we'll bring you the latest throughout the hour. plus, as oil prices fall, dennis gartman is making a bold call about where the price of crude is headed in the long-term. it's not pretty that prediction is coming up.

we start off with twitter. julia boorstin spoke right after earnings broke in the last hour. what's the latest there? >> while user growth to 284 million monthly active users was pretty much right in line with active expectations, he says the company's real base is growing much faster than expected thanks to the adoption of law of the new mobile profiles that are increasing engagement as well as the number of views. now, said though the business model is shifting to have more of its users be logged out rather than logged in, that should not hurt its revenue growth. >> we don't think they're less valuable to advertisers for a number of reasons. those users come to twitter on a logged out basis are coming because of a directed search. they're searching for an interest, a hash tag or a user. so they're already coming into the platform with interest. and secondly, because of our ability to organize content around those interests around

the world cup with the kind of world cup experience we developed, we know that we can deploy experiences that are super valuable and engaging to the logged out audience. >> i asked about concerns about management upheaval and peter thiel's criticism that twitter is horribly mismanaged and there is probably a lot of pot smoking going on here. here is what costolo had to say. >> what i lack for in hair and 20/20 vision i more than make up for in self-confidence. the team have i many place and the strategy we've got we love and we all believe in it. and we know when we're successful, twitler be useful and vital to every person on the planet. >> and while q-4 projections are coming in on the lower end, costolo pointed out guidance is actually a raise for the company. twitter's earnings call kicked off moments ago. i'll be monitoring it and back within the hour with any james.

>> thank you so much. let's trade twitter here. the context is past three months the stock is up 30%. second quarter they added a lot of net apps. so what do you make of the quarter? >> they're trying to get a metrics that nobody can understand. so it's the analysts community is only looking at maus. that's all they're concerned with. they want to sell is stock based on that. i can it has more value than that. i'm still long. i would add if the sell-off continues like this. >> i'm not sure i totally agree with steve. but we're talking about this with bob is who going be with us later. is the logged on or nonlogged on issue that people are having trouble with. twitter keep telling us what metrics we're supposed to follow. i think the street has been listening. a lot of analysts reports i've read in the past week have talked about the nonlogged user. but when you talk mau user is supposed to be a lot of people were closer to 287, 2888. and even though they're nailing on ad revenue and the stock coming into, that's part of the problem because it has

performed. i think that's why it's getting pushed around. >> 284 monthly average users, there is still 23, 24% growth year-over-year, which is not fantastic given the valuation of the stock. >> right. >> but it's not a disastrous quarter either. it just wasn't good enough. how you trade the stock? 56 it traded up to a week ago. we bottomed out around 30 bucks. so 43, which is where i think it will print is a 50% correction. i think you buy it at 43 and play for the bounce. not unlike the bounce you saw in netflix. and to a certain extent, the bounce you're sort of seeing in samsung. >> they do have an analyst date the middle of november, november 12. >> that we'll talk would be bob when we coming on. this is a stock people are buying for growth and they're looking for different metrics. >> i don't like the idea of switching metrics. >> it sounds kind of fishy. >> a lot of people agree with you. >> i guess down 10% or more at this point. so, you know, maybe they can sort of push it off another quarter and see, all right, maybe given them the benefit of

the doubt. but it's not for me at this valuation, having missed on a major metric. >> for more on twitter, let's bring on bob. i want to go to you. i want to ask you about this logged in versus logged off user. the logged off user still not hurt revenue growth? it sort of doesn't make sense at the face of it there. >> are two or three questions you really want to ask. how big is that base? they said two to three x or maus. how can they monetize that device. 11% come through are coming through third party platform. they can't target directly. and 9% of them don't have any activity. you want to get an idea of the actual user base. and the activity side of things. if they're looking at timeline views, what is the right metric to go after it how should the wall street community gauge the performance. >> at what point do you say dick costolo, i don't get it. i thought it was maus. and now you're telling me logged

in versus logged off. isn't it getting a little confusing? >> it is. one of the top things wall street is a looking for is give us a way to gauge activity metrics how. do we think about that combined. because we want to think monetarization. >> 44 and change. does this quarter make you reevaluate that price target or $58 still in the cards? >> we put a preview out last week that we thought the cinema had really shifted the investor pendulum to the greed. it gives a nice entry point. the analyst day coming up on november 12th. and will give a lot more about the long-term vision on the metrics. i think it will be a positive cat li catalyst for them. >> some of the other ones you cover, bob, what is being sold that you think doesn't make sense off twitter's earnings? >> i think facebook reports tomorrow night is our top pick

going into earnings. everything we've heard about the fundamentals of the advertising business for them is just tremendous. i think they'll do almost 15% sequential revenue growth. and the interesting part there is they still haven't turned on so many revenue levers. they have a long way to go. >> we'll check later. bob peck of suntrust. does it bother you that they keep switching the metrics? >> no. i actually like the fact that there is something to buy it for. because if it was just maus, i would not be in the name still. >> doesn't that make you think what am i buying it for right now if the next metric to look at is one that hasn't been identified? >> well, that's the question. if it's something they need to fabricate, i don't think that's the key. the key it is was mopub originally when they couldn't get up to snuff with maus. now we're looking at lauged off versus logged on. when you're looking at a link and you get driven into that twitter hub, i think that has to be quantified. i think it's a matter of time before they quantify it. it's not that's it never going

to be quantified. i'm still in the name. >> we'll keep track of twitter here. it is down by nine 9 plus%. oil prices dipping below 80 bucks today. but this are factors brewing that could lead to a virtual oil price collapse, as in 10 bucks a barrel kind of collapse. he'll explain. that's next. buffalo wild wings, manitowoc, all moving higher. all those earnings reports straight ahead. uld use some hel. smart sarah. seeking guidance. just like with your investments. that sets you apart. it does? it does. you're type e*. and seeking another perspective is what type e*s do. oh, and your next handhold... is there. you don't have to go it alone. e*trade gives you the support and guidance to make informed decisions. are you type e*? opinions. there's no shortage in this world.

who do you trust? whose analysis is accurate? how do you make sense of it all? a simple, unbiased stock score consolidated from the opinions of independent analysts... is that too much to ask? nope. equity summary score, powered by starmine, will help you execute your ideas with speed and conviction. and it's only on fidelity.com. open an account and find more of the expertise you need to be a better investor. ♪ there's confidence... then there's trusting your vehicle maintenance to ford service confidence. our expertise, technology, and high quality parts means your peace of mind. it's no wonder last year we sold over three million tires. and during the big tire event, get up to $140 in mail-in rebates on four select tires. ♪

♪ one more time >> it's my wedding song. >> all right. crude oil falling between $80 a barrel to the lowest level in two years. wti crude has plunged 25% from highs hit in june. and today goldman cut its target to 75 bucks a barrel. our next guest says prices will continue to fall in an all-out collapse could be in the cards. let's bring in dennis gartman, the editor of the gartman letter. good to see you. >> always good to be seen, mel. >> what kind of collapse are we talking about, and what are the

circumstances around this collapse? >> well, there are a number of things going on here. first of all, let's understand the term structure in crude oil has been overwhelmingly bearish. you have taken brent already to con tango. it's heading to a there is more than enough crude out there right now to meet any kind of demand. more is coming. what is more important to me, something that caught my eye is petroleum reserve under the rulings required under the spr, we need to keep 90 days worth of our last year's net imports of crude in the spr. right now we're keeping, given the fact that we are soon to become a net exporter of crude oil, clearly we're importing less and less crude oil on a daily basis. we have according to the iea 245 days worth of crude oil in the spr that if i were the obama administration, i would already be selling. why they haven't begun to do that is beyond me. and then an article that i

thought really was fascinating and no one has talked about, lockheed martin has announced that within five to ten years, and i think it will be sooner than that, it will have an operative fusion reactor. fusion is going to be the great nuclear power of the next 150 years. and finally, we are driving less and less. we are using so much less gasoline than we ever have in global terms, in national terms, per capita terms. all of those things i think are going to be weighing heavily on crude oil. and where can it go? a lot lower. a lot lower. >> let's dig into that then. in terms of the short-term, would you agree with goldman's call that it's $75 by the first quarter of next year. a lot of people on the street. bank of america says 75 buck by tend of the year. >> sure. >> and then longer term, it is 10 bucks? is that what we're talking about? >> well, no one wants to go on record and say that crude oil is going go to $10. >> you already told our producer

10 bucks, dennis. come on. you're either on the record with that or not on the record with that. you already gave it up. so what is it? >> i think crude oil goes demonstrably lower over the course of the next several years. it goes the way of whale oil at the turn of the 20th century. when crude oil came online. energies tend to be replaced one by a different type. and the old energy loses its value completely. crude oil is going to go a lot lower. who cares whether it goes to $50, $40. that's not what is important. the trend is clearly downward. oil prices are going to go a lot farther down. if i have learned anything in, this i guess i should be more retrospect when i speak with our producers in the future. and not put numbers on them and simply say that the trend is clearly downward. prices are likely to go demonstrably lower than anybody wants to anticipate. >> right. >> opec has lost control. and we have new fuels that are eventually going replace crude

oil. wand the backwardation disappears overnight in wti and brent in contango, crude bidding for storage tells you uthat the supply already is abundant. >> and you may have regretted saying the $10 a barrel level. but at the same sometime what you just said is more shocking. comparing oil to whale oil, which is obviously, you know, it's nowhere now. is a more shocking prediction. you're basically saying that oil will be completely replaced at one point by another energy source. >> if what lockheed martin has reported, and it was reported in a large number of areas, but nobody seems to be pick it up. i can't imagine that lockheed martin's people have lied. if lockheed martin has a fusion reactor that is going to be commercially operable within ten years, that takes care of energy supplies for the world. suddenly it makes fossil fuel absolutely unimportant. could lockheed martin have lied? could all of the reports have

been fallacious? it's possible. have i my doubts as to whether that's true or not. we'll see. but i'm surprised that that has not gotten any coverage. and right now we have to say with 245 days of crude oil in the spr, why the obama administration has not released some. and i have to suspect that they probably shall. that alone will take $15 off of crude oil in a very short span of time. so i'm sorry, but crude oil, its future is now behind it there is no future for crude oil in the coming 15, 20 years. i'll be dead, however be, i that time. >> okay. dennis, we're going leave it there on that note. dennis gartman of the gartman letter. let's unpack what dennis says. ing a lot of people disagree completely with the prediction that crude oil is going to be complete le replaced. >> replaced by nuclear energy? entirely? that to me is a crazy thing to say. >> you guys think it's bunk. but threw there is another part of dennis's thesis which the spr levels are too high and the

administration has to sell which could put near-term pressure on. >> you can see there are supply-demand dynamics that could come out of whack. one of the big ones will be at one what point do we start to see cap x budgets being severely cut and production going down a lot. >> sure. >> then you'll see a step function down first before that happens. >> and then demand will catch up with supply. >> i think you'll see prices -- >> all of that will happen. that dynamic will happen well before the fusion wave. >> it has happened time and time again. boom and bust, boom and bust, that's the psych to feel industry. >> and what karen and i are both saying is eventually there is this catch-up mechanism. we know non-opec supplies is overwhelming the market. and opec probably doesn't care right now when you consider who controls opec. i don't think this is case where oil prices technically to get to 75, they're already going to have to be at $75 by the end of the year if you look at where oil prices are now. it's not a surprise to say demand is nowhere near where supply. >> what is the trade?

>> since -- exxonmobil has traded awful since the middle of july specifically when the stock was trading around 104. i believe on october 15th, 16th when it traded down to 88 on about two times normal volume, i think you might have put in a double bottom back to levels we last saw back on january. the good news is they report this friday i believe. not a lot of time to wait. most of all this, if not all of this move in crude has been priced into xom. i think you get long ahead of earnings friday. >> so i think post the midterm elections, guys are going to be looking for where they can make up their year. i think they're going to look to energy, a halliburton, a schlumberger. >> no concerns that oil is too low so their customers will be cutting back? >> put it this way. that number, goldman sachs, when oil was $140, that oil was going to $200, it went down to $40 or thereabouts. people are very bad at predicting the price of crude. also, this is not coming in when

it was $110. $5 away from where they think it's going. >> right. >> and $70 is where cap x becomes a little crimped. so i think that going to year end for a trade, you're okay buying the surface. >> results of the brazilian elections are. in the initial market reaction is sharply negative. brazilian stocks falling more than 4% today after dilma rousseff barely eked out a win. on friday two of oour traders battled over the ewz with tim seymour making the bold case, take a listen. >> usually during contentious elections markets sell-off in the elections and rally thereafter when they know the news wasn't quite as bad. remember, you have priced in 80% of a dilma victory. if you get another win you have a market that is going to rally up for two or three straight days. if dilma winnious priced in at least 80% of the risk reward. it's a no-brainer. >> now what, tim? >> as steve warned me, don't ever say no-brainer. but on monday, can i say anything different? in fact we talked about this friday night.

all you can do is come in this morning and buy brazil down 10% which then it closed down five. so what happens next? dilma has to make cabinet appointments there are things that could be positive. one is your finance minister. people are talk about fraga, who is a well-known guy to western investors. this could be reaching across the aisle. but this was a very divisive election for brazil. what has to happen now is the country does need to come together. and in my view, what i said. over 80% has been priced in. if you look at the companies that will perform in this environment, at least go with the companies that have sales in dollar and have cost in real which will probably devalue a bit. the state-owned prizes which are petrobras, these are the ones that were most hurt under dill map. these are the ones still under the most pressure. but when you look at the private sector, when you look at the companies that benefit from dollar exports, this is where you can play in brazil. i say what i said. you have a market that to me is

priced in an enormous amount of negativity. and in the emerging markets, it's usually the buying opportunity after the elections. >> you don't like the state owned enterprises and you like what instead? and is ewz not good because it's too much state owned enterprise? >> the ewz is still heavily tilted toward petro bass and valle. i would be look at banks. one of the best banks in the world. cbd is walmart's best buy of brazil. a consumer play. some the data data growth is leading to margin that are much, much better for these guys. >> all right. coming up next, it's not just twitter dominating the headlines tonight. a slew of other earnings from amgen to cliffs natural. how to play all these big moves. that's next. from record-breaking highs to major market meltdowns, every night the "fast money" team makes sense of the trades.

serving up in-depth analysis and actionable advice. >> i would be a seller of the xoe. >> all to help you prepare for the next trading day. >> volatility has almost come down in half in less than a week. >> this is "fast money." >> the biggest rallies happen within bear markets. >> have a question for the "fast money" traders? tweet us at cnbc.fast money. ameriprise asked people a simple question: in retirement, will you outlive your money? uhhh. no, that can't happen.

that's the thing, you don't know how long it has to last. everyone has retirement questions. so ameriprise created the exclusive.. confident retirement approach. now you and your ameripise advisor can get the real answers you need. well, knowing gives you confidence. start building your confident retirement today.

an unprecedented program arting busithat partners businesses with universities across the state. for better access to talent, cutting edge research, and state of the art facilities. and you pay no taxes for ten years. from biotech in brooklyn, to next gen energy in binghamton, to manufacturing in buffalo... startup-ny has new businesses popping up across the state. see how startup-ny can help your business grow at startup.ny.gov

he calls it dancing. buffalo wild wings trading higher in the after hours session. let's get back to headquarters. >> melissa, what we have are buffalo wild wing shares up about 4% in after-hours trading on 300,000 shares worth of volume. this after the company reported earnings that beat analyst sales estimates. comparable store sales for the quarter ahead of certain analysts estimates. their forecast for comparable forecast sales also better than some estimates. the company ceo saying that they will raise prices by about 3% at the end of november to combat certain minimum wage hikes as well as increases in chicken costs. so they will raise menu prices

to accommodate increased costs for food and labor. those shares again, melissa, up 4% in after hours trade. back over to you. >> thank you. chicken wings, i don't know if you know this, chicken wings are up 25% in two months. the question is can they -- >> i think so. operating march has hung in, hung in at 8%. that's a good sign. remember, this is a stock that sold off from 170 or so earlier this year. so to answer your question, yes, i think they can pass it on. yes, i think this is a good quarter. 22 times forward earnings is not crazy for a stock like this. and i think so it's going to force the shorts to recover. so i could see the stock going higher from here still. >> speaking of. >>. a slew of other names reporting after the bell. let's get the play. amgen beating the top and bottom line lines. >> it's not a crazy valuation if you compare to it some of the big cap pharma names. when you consider the fact that they have major major drugs of pipeline that fiez worry love to

have, this stock is down right cheap. this is a great quarter. well said it's going to continue to go higher. i believe it pushes through 150 and it's on its way to levels we've never seen before. >> cliffs nauls. grasso? >> a stock 50% short interest. so it is susceptible for a short covering spike. but ever buy on the dip has been a wrong buy. you to believe that the world is getting better here. soly still not be there. >> i actually own cliffs. and to me, the reason why people want to sell brazil is the reason cliffs is struggling here. iron ore supply is going to overwhelm this market. and i think they're going to overshoot to the downside. but i think cliffs is one of the best balance sheets and i stand the name. >> manitowoc just came out missing the bottom line. >> they have some explaining to do. very early october, they were at -- i'm not sure if it's credit suisse or where, but they talk a good story. and then ten days later, guided down, which is very similar i think. i haven't been able to go

through every line of what they're announcing today. but part of their whole reason for being a crane company and a food service company is one of the businesses can when one is doing well, the other is doing poorly and you can balance them out. now neither of them are doing that well. the food service business doing okay. but should it be doing a lot better. they're going have a lot of explaining to do 10:00 tomorrow on the call. remember, relational is there. they have a big position. their mandate is split the company up. you're not doing shareholders any service by having these two totally disparate businesses. break them up. >> with the company falling out of bed in after the hour position, do you think it's a buy on this pullback? >> i'm already in it. i probably would buy more tomorrow. if it trades liquidly there. but i think the company, they could face a proxy fight or maybe they could cave in. i'm not sure. >> more cranes or more food service? the crane business is the business that seems more important and the one that was -- the bar is lower for them

to beat. >> well, the u.s. business and the crane business has not been great. that's not just them. >> got it. >> coming up next, the twitter conference call now officially halfway through. the latest headlines fresh from the break. and could that delay to the delaying of the muscular dystrophy drug? we'll be sitting down with the ceo of pro sensa later on. we believe every life deserves world-class care. as one of the top four hospitals in the nation, over 100,000 people from around the world come to cleveland clinic for care each year. and we're ready for you with a second opinion or a same-day appointment today today today and everyday. call today, for an appointment today. tdd# 1-800-345-2550 even on the go. tdd# 1-800-345-2550 open a schwab account, and you could earn tdd# 1-800-345-2550 300 commission-free online trades. tdd# 1-800-345-2550 so if you get a trade idea, schwab can help you take it on.

tdd# 1-800-345-2550 we're getting a lot of questions tdd# 1-800-345-2550 about organic food stocks. tdd# 1-800-345-2550 [ male announcer ] sharpen your instincts tdd# 1-800-345-2550 with in-depth analysis by schwab experts. tdd# 1-800-345-2550 and if you want to run your idea tdd# 1-800-345-2550 by a schwab trading specialist, tdd# 1-800-345-2550 our expertise is just a tap away. tdd# 1-800-345-2550 what's on your mind, lisa? tdd# 1-800-345-2550 i'd like to talk about a trade idea. tdd# 1-800-345-2550 let's hear it. tdd# 1-800-345-2550 [ male announcer ] see how schwab can help tdd# 1-800-345-2550 light a way forward. tdd# 1-800-345-2550 so you can make your move, wherever you are, tdd# 1-800-345-2550 and start working on your next big idea. tdd# 1-800-345-2550 ♪ tdd# 1-800-345-2550 open a schwab account and you could earn tdd# 1-800-345-2550 300 commission-free online trades. tdd# 1-800-345-2550 call 1-877-670-3357. tdd# 1-800-345-2550 or visit schwab.com/trading. tdd# 1-800-345-2550 schwab trading services. tdd# 1-800-345-2550 your go-to for trading know-how. tdd# 1-800-345-2550 ♪

still ahead on "fast money," twitter shares sinking after its quarterly report. the conference call is about halfway through. we have the latest coming up. plus, new potential ebola cases revealed today. but many of the biotech drugmakers are barely moving. we have the latest on the pipeline. and one trader making a big bearish bet on target. we have the details coming up. but first, let's start with twitter. julia boorstin is on the conference call with the very latest. >> the twitter earnings call, the ceo said the company's new ad formats are working with ad growth strong across all major channels. he said the company saw meaningful contribution from new ad formats, including mobile app downloads, website cards and

promoted video. but fabric, the company's new tools to enable twitter to be the infrastructure for all of mobile apps. ceo dick costolo has talked how he believes fabric is one thing all mobile developers need to be the infrastructure and backbone of their apps. he also talked about how he wanted to really increase the pace of execution at twitter to really help it achieve its potential much more quickly. now the cfo warned they should expect timeline users or the flat and q-4 ad revenue could be as much as 30% higher. now he said the declines in time per alternative monthly viewers would be designed to make twitter more efficient. a lot of statistics for investors to parse there. now, there are also some comments about the fact that q-4 revenue projections are lighter than wall street expected. no noto said the company is trying

to be accurate with its guidance and not bet on twitter out-performing its guidance like it has in the past. melissa? >> thank you so much, julia boorstin. let's get back to bob pack, the analyst with suntrust who is here in studio monitoring the call for us. what do you make of all that? that's a lot for investors to digest. >> yeah, i think the big takeaway there is the guidance they gave which is below mid street on the revenue side is not conservative. it's probably more realistic. and i think they're trying to set a new tone so the street doesn't get too far aahead. on the mau, they mentioned there is a one to two million impact. they're taking over in asia. that's a bump. the coverage remains low. and they point to it as the biggest opportunity to catch up to other social networks like facebook. but two quick points here. the timeline views per mau. the newer people that come on, the newer cohorts, that starts lower. that's when they need to ramp up to match the other cohornets. the ad revenues for timeline view is going to grow about 30%. last year it was 50%. so that disappointed a little

bit as well. >> and quickly, bob, we are at pretty much session low down 10.6%. what is your inclination at this point any know we're halfway through the conference call. are you feeling better about your buy rate thong stock? >> i think the top two things are really maus, what can the numbers truly be. how can doh you get to 400 or 500 maus all the time. how do we tap into that and ultimately, the guidance for the short-term players. looks at their guidance as on pace where the street. >> thanks for that. we'll check in with you. guy adami how. you feeling about all of this? >> again, it's getting close. it's going print 43 and it's 43.5 right now. at 43 you close your ice and i think the risk reward sets up well. it's a 50% correction off the range we talked about earlier in the show. this is your opportunity to buy it for a trade. >> all right. let's take our position here. we have facebook. earnings report tomorrow. when it comes with it comes the unlocking of 178 million shares held by what's app employees.

now it's time to take your position. let's go around the horn. tim? >> i like facebook. i'm less worried about the lockup, especially when i look at the amount of people that want to be in this name. the valuation to me is slightly south of 40 times makes sense for the growth they're giving when you look at them compared to twitter, this is the place people want to be. i think they're going reward investors. >> i don't know if twitler never have the scale that facebook does, but they have an incredible head start. i'm long face boog. i'm much longer twitter unfortunately at this point. but i think facebook goes another 5 to 10% higher. >> karen? >> i don't think the lockup really makes a difference here. it's not an unsurmountable -- first of all, it's not clear that it's getting sold when or if at all. and even if it were, it's only three or four days volume which in one trade would be a lot. but that i don't think is the issue here. >> guy? >> huge operation margins, north of 55%. i said for a while i think it's

going to 85 post earnings. i'd sell it then there is a little sell-off on the become of twitter. i think they're mobile numbers are going to be great. i think it goes to 85 tomorrow. time for pops of and drops. tim? >> this is after friday's 9%. this is down almost 30% from the highs. this is a name i've been very clear i stay away from. i don't go near it. any miss, this stock could lose another 20%. wait for this thing to get down to a valuation that makes sense. >> a pop for micron, up 4%. karen? >> they announced a billion buyback today. they haven't really been this the market that much. they have a lot of cash flow. they also brought back a convert. so they're feeling pretty good about their story. >> drop for wendy's, down 5%. >> guy? >> they downgraded the stock they reported in november. they have headwinds just like mcdonald's does. it looks like it's a cheap stock. it's not. the best thing about it. >> morgan smith goodwin. >> msg. >> no. it's the redhead in those commercials.

>> oh, who plays wendy? >> no. no she doesn't play wendy. she is the one that sings. >> the girl in the ad campaign? >> thank you very much. >> not sure why we're talk about her now? >> she is adorable. >> and the chicken nuggets best on the market. i don't know if you guys know that. >> such a tangent. >> but i digress. >> we got a drop for tesla. >> the two-day moving average which is 224 right now has been real good solid support. it broke below that. now it's all about -- it's all about model s sales or lack thereof. down 26% year-over-year through september. i would wait until it gets above 224 to get back into it. >> we have a pop for baby elvis. a 10-week-old boy in london is rocking a pint-sized pomp dour. he was born with black hair. his mom credits her boy's rockabilly locks a mars bars during her pregnancy. >> what?

>> when was the last time you had a mars bar? do they even sell mars bars in the united states? >> there is nothing in them. >> the zaganuts. the drug today by six months and pumping up one competitor's stock. we'll talk to the death row of prosensa right after this break. . . goal is to grow. gotta get greater growth. i just talked to ups. they got expert advise, special discounts, new technologies. like smart pick ups. they'll only show up when you print a label and it's automatic. we save time and money. time? money? time and money. awesome. awesome! awesome! awesome! awesome! (all) awesome! i love logistics.

there was no question she reminds you every day. but your erectile dysfunction-that could be a question of blood flow. cialis for daily use helps you be ready anytime the moment is right.

you can be more confident in your ability to be ready. and the same cialis is also the only daily ed tablet approved to treat symptoms of bph, like needing to go frequently or urgently. tell your doctor about all your medical conditions and medicines, and ask if your heart is healthy enough for sex. do not take cialis if you take nitrates for chest pain, as it may cause an unsafe drop in blood pressure. do not drink alcohol in excess. side effects may include headache, upset stomach, delayed backache or muscle ache. to avoid long-term injury, get medical help right away for an erection lasting more than four hours. if you have any sudden decrease or loss in hearing or vision, or any symptoms of an allergic reaction, stop taking cialis and get medical help right away. ask your doctor about cialis for daily use and a free 30-tablet trial.

regal entertainment soaring after hours on earnings. let's get back to dom at headquarters. dom? >> melissa, regal entertainment is the biggest operator of movie theaters in america. they beat bay penny per share. the revenues were short of analysts' estimates. it wasn't a great blockbuster summer movie season. regal said it's going to explore strategic alternatives, including a possible sale of the company. they also announced a special one-time dividend of $1 per share. hence what you see on the screen, a 12% gain in the after market session. back over to you guys. >> dom, thank you. karen? >> phil anschutz, very, very savvy investor. he controls the situation here. i wonder what he is doing. he wants to get the cash out with the dividend and via a sale. i don't know.

it seems unilaterally for sale. >> are you going to take a look at this tomorrow? >> yes, it is worth taking a look at. new headlines in the ebola outbreak today. now a 5-year-old boy is being tested for disease at bellevue hospital here in new york city. meg terrell has been watching closely as well as the treatments coming down the pipeline. meg? >> it's been a crazy day. and at the end of the day, we got updated guidelines on health care workers returning from the affected countries in west africa. this after the governors of new york and new jersey agreed that folks should be quarantined if they treated people over there. that caused a lot of consternation. as a nurse just got discharged today. the cdc coming out with more nuanced guidelines that continues between the states and federal guidelines. and this 5-year-old boy at bellevue. we don't know if he has tested positive for ebola. we know he was taken to the hospital last night, developed a fever this morning. today dr. frieden from the cdc said he was presenting in an

unusual way for it to be ebola. so we're thinking maybe it isn't ebola. but we still don't have the test results back. those are expected this afternoon. and then the doctor who is being treated at bellevue, dr. craig spencer, who has tested for ebola, the only person in new york to have done so, we know that he is in serious but stable condition. we know that he received plasma blood therapy donation from another ebola survivor. and we do know he received an experimental antiviral maybe by chimerix. that used in a lot of patients relatively speaking now in this ebola situation in the united states. so there is some question is that one emerging as a favored dug here by doctors? we know it's a pill. we know it's easy to administer because of that. and now there is questions about will it get deployed in trials in west africa. the company is now in discussions about how to do that. but they are working on a trial here in the united states. >> just taking a look at the stocks, the sort of ebola biotech basket since maybe the beginning of october or so, maybe even mid-september,

chimerix seems to be the one who has been doing the best most consistently. i don't know if the market is telling us they believe that's the one that is out ahead. there any more catalysts in terms of medicines to be deployed or the cdc or w.h.o. weighing in? >> it's about news flow. on chimerix it's been that patients are receiving the drug. we do know that thomas eric duncan in dallas passed away despite having received the drug. that's one patient. he got treatment pretty late. it's hard to gather data from the individual circumstances. so there is going to be news flow coming out. interesting on zmapp, which seemed to be the drug of choice initially made by a private drugmaker, they're trying to ramp up that production by involving other biotech companies including amgen actually, trying to do the traditional biotech way of drug development instead of production it in tobacco plants which they think may ramp it up faster and in bigger quantities that is going to be some news catalysts on that end and all of these things kind of trade

together. how that will affect chimerix ander serepta, we'll see. >> that was wrong, because here it at. 18 1/2. good news for the stock. it's not been good news in terms -- i got to be careful how i talk about that. but i still think you're going get one more up in the tekmira. >> meg is going to stick with us for the next story. shares of biotech companies are tanking on news the fda is asking for more information on muscular dystrophy treatment pushing back until 2050. one company benefitting from sarepta's delay is prosensa. its muscular dystrophy drug is now in review by the fda. joining us is hans schikan. hans, greet have you with us. thanks for your time. >> thanks for the invitation. it's great to be on your show. >> a lot of analysts are now

saying that this delay on the part of sarepta's drug is going to put you six months ahead. can you give us a time frame in terms of the next approval or the next submission process with the fda and when possible approval would be? >> well, let me start by saying we are all in this together. i mean, the american companies pioneering in rare diseases, very few in muscular dystrophy. the company working in the field, research groups, the patient organizations, the experts, any setback for anyone is a setback for this whole community. so my empathy goes to sarepta and to the patients who are eagerly waiting to be treated as well. but now about prosensa. we have started our submission process. and as a matter of fact on the 10th of october we submitted under a so-called rolling review. a rolling submission, our first models of our new drug application. that is possible because we have a so-called breakthrough therapy

designation and fast track which whereby they try to get drugs for needs earlier to patients. >> in terms of potential approval, i know it's early in the process. but credit suisse is already putting out there that perhaps potential approval could happen year end 2015 or first half of 2016. does that sound about right to you now? >> well, in our case we have started our submission, as i mentioned on the 10th of october. we will be submitting all the parts of our file in the next few months. and we hope we will be able to have that fully processed by year end. and then of course the file has to be accepted by the fda. and then the review will start as well. so if everything goes well, that could lead to a potential approval somewhere by the middle of next year. but that's too early to speculate at this moment. but those are the timelines which will be applicable if things go as planned. >> mr. schikan, it's been a rocky development timeline both for you guys and sarepta.

you had a late stage study that didn't meet its primary end point, declined a partnership with glaxosmithkline. now you're redosing some of those patients. but you do have the path forward at the fda. can you comment on sort of your expectations given that that trial didn't immediate its end points? and also why you think that you guys are going forward when sarepta is having so much trouble? >> well, let me start by saying that indeed we have had a number of interaction was the fda. already in january, in may, in september and october. so we had a number of very constructive interaction was the fda where we shared the data of the all over program. and we think that we have one of the largest data sets right now and more than 300 patients and more than 450 in treatment years. so apart from a long-term study of three and a half years, we also have three placebo controlled studies. and all that data we shared with the fda. on the 2nd of june this year we

shared with the fda on a potential path forward, a so-called accelerated approval pathway that means you can submit your data and that you will have to supermanned that with more data. but you can do that prior to approval and after approval. so in our case, the accelerated approval submission process has started. and if everything goes well at a certain moment we hope them to get approval. and after that, we can still submit that additional data so that the accelerated approval which we will have received one day can then be converted to a full approval. but that can come a few years after the approval is given. >> hans, thank you for your time. appreciate it. hans schikan, the ceo for prosensa, which does have the ticker rna for all of you who are wondering. we asked that question or you asked that question about meeting the fda. in sarepta's case it seems so surprising. what the fda was questioning was the data, the inconsistencies of the data when it comes to

disstroh phin. >> a lot of questions are on how they're measuring disstrohphin. that's is how you're measuring that. but the delay for sarepta is about getting additional data on new patients that haven't been treated yet. they have a phase 2 study they've done that has just been in boys. now the fda looking out 168 weeks. so there are a lot of questions about the communication going on with the fda, why we're seeing one company move forward while the other company isn't. >> all right,ing meg tirell, t you so much.

we asked people a question how much money do you think you'll need when you retire? then we gave each person a ribbon to show how many years that amount might last. i was trying to like, pull it a little further got me to 70 years old i'm going to have to rethink this thing it's hard to imagine how much we'll need for a retirement that could last 30 years or more.

so maybe we need to approach things differently, if we want to be ready for a longer retirement. ♪

the holiday shopping season is fast approaching and some are putting a target on the back of one well-known retailer. mike? >> it's common to see heavy options volume right before an earnings announcement. but today we saw heavy put buying in target, even though their earnings isn't going to be released until november 19th. these november 22 expiration 59.5 strikes puts for about a dollar are making a bet that

target could fall. and maybe it's not just earnings that they're making a play on. target obviously made a couple of announcements. one of them related to kwon line sales and getting going to pick up the items at the store in a very short period, ostensibly to compete with amazon. also, there are concerns about deliveries to los angeles area ports. and target is one of the five largest importers at those ports by weight. so it could be the issues that are going on at the ports. it could be their competition with amazon, or it could be earnings. >> all right. thanks for that, mike. we're watching kohl's in the after hours section sink. i'm just curious in terms of that area, is there anything that you like, the discountee lower end area? >> i like target. i think that so much negativity has been priced into forget the security breach. it's all about canada, really. can they turn the business around. i think the valuation, there is nothing -- the problem is that the near term catalysts are very few. but this is a stock in the

longer term i think will catch itself. coming up on "mad money" tonight, the ceo of the center of a boardroom battle. >> a lot of people who are not that close to merger and positions might say listen, allergan is north of 50. if it was really so great, why didn't allergan buy value? >> the answer from allergan's ceo might surprise you. don't miss cramer's exclusive coming up at the top of the hour. meantime, we have your first move tomorrow when we come right back. stay tuned.

twhat do i do?. you need to catch the 4:10 huh? the equipment tracking system will get you to the loading dock. ♪ there should be a truck leaving now. i got it. now jump off the bridge. what? in 3...2...1... are you kidding me? go. right on time. right now, over 20,000 trains are running reliably. we call that predictable. thrillingly predictable. so right now if you get the 15 gig plan, we'll double the data and make it 30 gigs for the same price. 30 gigs? wow - that's a lot. you don't have to do that for me. oh, that's ok... (interrupting) seriously, i wouldn't want you to get in trouble... it's the same plan for everyone. families...businesses...whoever. riiiiight. (yelling) no celebrity treatment here! (yelling) there really isn't any celebrity treatment. just a normal guy, getting a great deal. we're just saying it loudly for some reason. now get 30 gigs of data to share with family or your business. for a limited time, starting at $160 dollars a month.

ameriprise asked people a simple question: in retirement, will you have enough money to live life on your terms? i sure hope so. with healthcare costs, who knows. umm... everyone has retirement questions. so ameriprise created the exclusive confident retirement approach. now you and your ameripise advisor.... can get the real answers you need. start building your confident retirement today.

all right. we've got some breaking news. we all know the story about the 5-year-old boy who is being tested for possible ebola. we now know that he does not have ebola. he has tested negative, melissa. a piece of good news on that front. back over to you guys. >> thank you so much, dom. around the horn. tim? >> nike, sell at 90. sell some tomorrow. >> grasso? >> twitter. i still believe the name. i'm staying long. >> karen? >> on the back of this colson disappointment, if you can buy some macy's down around 57 or lower, i think it's a great buy. >> guy? >> facebook. >> ahead of earnings?

>> ahead of earnings. i think the mobile number is going to be great. >> and you're -- >> i do a little facebook. >> i'm melissa lee. thanks for watching. see my mission is simple, to make you money. i'm here to level the playing field for all investors. there's always a bull market somewhere and i promise to help you find it. "mad money" starts now. >> hey i'm cramer. welcome to "mad money" welcome to cramerica. other people want to make friends. i'll just trying to make you a little money. my job is not just to entertain but educate and teach you so call me or tweet me @jimcramer. could a clueless market be gained. can the dazed and